CNS Biomarkers: Monument Targets Schizophrenia, Anxiety And Cognitive Decline
An Interview With Steven Powell
Executive Summary
Steven Powell, chair of the board at Cambridge Cognition, talks about the group’s latest spin-off company, Monument Therapeutics.